Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
trading desk at etrade quoting .20-.30
just spoke to the trading desk at etrade.bid .27 ask .54
Just spoke to the e-trade trading desk. bid .223 ask .54
for what its worth,called the etrade trading desk and they show a .26 bid .59 ask
I just spoke ot e-trade re:pioe..they called there trading desk as I see last trade but no bid or offer...they told me bid .30 ask.60...obviously doesn't do much good but just passing along info I rec'd.hopefully early next week we will see the bid/offer
don't think they do.they just bought there priority voucher.i believe it gives them a quicker review on a future compound they may be looking to bring to market. is that coreect dew?
SRPT sells priority review voucher to GILD
dew
regarding RVNC.the stock is down from mid 30's to 14 in a year, and insiders have not stepped up to plate to purchase any stock and the insiders for the most part hold very little stock.Does that cause any concern for you?
So dew..that's what surprised me that you were buying the stock between 17-20..why wouldn't you wait for the news to come out and look to take a position at lower prices.if I'm not mistaken,they had said data on 001 would come out prior to 002
Just based on macro environment I think its more likely that IBB
will trade down to 2 year low of 217
biomaven/dew
do you guys have a opinion regarding esperion for their cholesterol lowering oral drug.seems there mechanism is different from CETP inhibitors.
JBEM
Any idea how much randall kirk paid for his position in sngx?seems like initially the position was started in may 2013 with a agreement with Intrexon.
I have been monitoring the stock price since you 1st mentioned a couple weeks ago and seems to be getting close to support of about 2.15...took a position at 2.30 and looking to add on any additional weakness.
thanks for your input.
JBEM/BOB
Not sure if you have taken a look at TRVN.may have the ingredients your looking for a possible investment.Big institution buying.great balance sheet.insider buying.and catalyst in 3rd qtr.
Would love to hear your thoughts.
good to see that a fibrinogen director stepped to the plate to purchase stock amongst this somewhat free fall.
Dew
I agree that the WS article added fuel to the fire but I'd think you have also thought sell off was long overdue.Just think there will be further capitulation that will offer better prices,understand it happens quickly,but a morning sell off and ibb index will be down 10% from highs,so a 10-20% decline will take some of excesses out and will be looked back as being healthy as we get closer to ASCO.
I assume you took large profits on ENTA as your long call was spectacular,but did you think 30 was a possibility in such short order after it hit a high of 50+ in December.
Always look forward to your comments
dew
why wouldnt all shareholders tender their shares if there is a offer of 50 per share for 40% of all shares outstanding given that if Roche walked away the stock would trade as low as 20 per share?What am i missing?
Dew
Ian fron SI has posted a couple times regarding Roche possibly walking away from deal.You have stated"chances are close to nil" that can happen.Has your % of that happening changed at all?If not,should he be able to continue to post the same ridiculous prediction over and over.
Dew
seeing Luly sell stock at 35 cannot be reassuring.I understand its part of a prior plan he set up,but doesn't he the option to cease that?
Dew
Would like to know what you think the probability is that Roche walks away from the offer for Fmi?
dew
didnt they announce a extension to tender for another month. i had tendered a majority of my position previously.does that mean my total amount tendered will be bgt by roche for 50pps?
Dew
Would you look to add to your position on a sell off tomorrow due to delay.
Dew
What are your estimates for 1st quarter sales of viekira for abbv?I remember you saying they should easily top 2b for the year.Not seeing any est. qtr sales numbers by any analysts,have you?
Dew
On CNBC today they were speaking of the Merck hep c data being presented at liver conference in April and if shows a 95+ success rate at 12 weeks can capture 20% of mkt.Can you either comment or refer me back to a prior post in which you spoke to that.
Dew,
After seeming hesitant on Ocrx due to the design of the phase 2b study,you purchase the stock.Is there something in the data released that gives you more confidence than previously.
Also interested if you have a opinion on Aerie Pharm.Starting phase 111 trials on a glaucoma drug that seemed to perform quite well in prior studies,in a large space with no approved therapy in 15+ years.Was interested in seeing a Regeneron officer on the BOD.
Thanks for all your comments.
dew
with that being said what is your opinion for the decline other than discounts, which should be offset by additional patients.
thanks again for your comments.
dew
are you attributing the continuous decline in ENANTA to the slashing in hep-c drug by analysts or a possible acquisition by ABBV of ACHN?
if neither can you give your opinion as to why stock has a 600 mkt cap given a est 275 million in cash by end of qtr and royalties of 100-150 per year for 2015/2016/2017.
im puzzled by the share price.
Dew
So when you look back at your late 2013 ENTA valuation model,is there anything that has changed in terms of pricing,potential market share,future competition,or anything else that would cause you to change your investment thesis today?
Always enjoy your comments.
Dew
Do you attribute today's decline in ENTA to analysts lowering est 2015 sales of hep-c revs?.you had recently posted a add to your position..could there be something more at play here.
Dew
You have spoken somewhat positively about AGTC over the last several weeks.Is that a company you are contemplating buying in your real life portfolio?Seems like a low mkt cap compare to others in their space.Is there a near term catalyst you are looking for.
Also appreciate your thoughts.
dew
can you repost what the royalty rate to ENTA is for sales of the Viekira Pak for the approved 3 combo regimen
dew
do you have a investment thesis on mirati,once again orbimed,baker,and tang seem to have big positions.
Dew
do you have knowledge of seattle genetics?Adcetris is their primary asset and expected to generate approx 200M in sales for 2014.Seems hard to justify a 4B market cap unless they can expand their use thru further indications.
seems like investors are concerned about PD-1 antibodies taking market share away due to the seemingly highly effectiveness of these drugs.
so, my question is your thoughts of PD-1 effectiveness moving forward as well as thoughts of possible combination therapies,such as the one announced with BMY a couple weeks ago.
Baker Brothers seem to be buying stock hand over fist throughout the year between 30-35,which put this stock on my radar.
dew
im not sure if you posted your thoughts on cerus corporation in the past,as i remember you may have,but seems like with approval in europe for there intercept blood system and approval in USA for there intercept blood system for plasma and not much competition,valuation looks low(450m)at these levels.
would you care to share your thoughts on cerus from a investment standpoint.
dew
you have talked about owning enta,fmi,cnat in your real life portfolio.any others you would like to share with your readers.
always look forward to your daily comments.
dew
is it your feeling that after the tender from roche(which is oversubscribed)is completed that the pps of foundation medicine will be trading below the tender offer given the activity since the announcement.Or is this something that you dont have a grasp on.
do you still feel about 50-75% of all shares tendered will be filled?
selling at 50 short term or 40 long term will result in the same after tax gain for myself.trying to get a grasp as the best way to attack this as my long term gain will take place in oct 2015.do you have a feeling if stock can trade above the tender price in the not so distant future.
any color you can give is much appreciated.
Dew
I'd like to know if you have a investment opinion on pharmacyclics.seems to be a 1 trick pony( but a very successful one)imbruvica since approved only a year ago has generated close to a billion dollars in sales and is partnered 50/50 in profits with j&j and shares developmental costs.seems extremely expensive at a 11 billion valuation give all the competition.any thought you may have on future imbruvica sales 3-5 years down the road and if you see this as anything j&j would think about acquiring.
Any thoughts?
dew
any comments regarding the conatus news.obviously more than a sell on the news.
Dew
Somewhat surprised you did not include fmi in your 2015 picks for contest,given your valuation model you had outlined many months ago.
Dew
Do you think that today's news regarding express scripts decision to back the abbv compound in some way plays to what FMI is doing, in that what ES has been saying is if we don't curb drug prices our health care system simply cannot afford the costs, and in essence a FMI test identifies the best personalized drug to give to each patient which can result in a huge savings to insurers.
Any comments would be appreciated.
Dew
With ENTA/ABBV on the verge of getting approval for there HCV regimen which will trigger a milestone payment that should give ENTA close to 300M in cash and a royalty stream amounting to over 100 million dollars a year and the stock closes at its lowest point since October 1st.
The inefficieny of the market on a short term basis never ceases to amaze me.